Comparative Pharmacology
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus KEFLIN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPODOXIME PROXETIL versus KEFLIN IN PLASTIC CONTAINER.
CEFPODOXIME PROXETIL vs KEFLIN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
Cephalothin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity, leading to cell lysis and death.
200 mg orally every 12 hours
1 to 2 g IV or IM every 4 to 6 hours. Maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min).
0.5-1 hour in normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days.
Renal: 60-80% unchanged; biliary/fecal: minimal (<1%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic